Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor β1-mediated activation of intestinal fibroblasts

British Journal of Surgery

Volumn 96, Issue 5, 2009, Pages 541-551

  Burke, J P ^a,c   Watson, R W G ^c   Murphy, M ^c   Docherty, N G ^c   Coffey, J C ^b   O'Connell, P R ^a,b,c  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; PLASMINOGEN ACTIVATOR INHIBITOR; SIMVASTATIN; SMAD PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; CELL ACTIVATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; INTESTINE CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL COMMUNICATION; CELL CULTURE; COLON; CYTOLOGY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; WESTERN BLOTTING;

ACTINS; BLOTTING, WESTERN; CELL COMMUNICATION; CELLS, CULTURED; COLON; CONNECTIVE TISSUE GROWTH FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROSCOPY, CONFOCAL; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIMVASTATIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 65249154053     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6577     Document Type: Article

References (39)

1. Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007; 102: 439-448. (Pubitemid 46160558)
2. Rieder F, Brenmoehl J, Leeb S, Schölmerich J, Rogler G. Wound healing and fibrosis in intestinal disease. Gut 2007; 56: 130-139. (Pubitemid 46044899)
3. Grassl GA, Valdez Y, Bergstrom KS, Vallance BA, Finlay BB. Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis. Gastroenterology 2008; 134: 768-780.
4. Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis 2004; 10: 55-60. (Pubitemid 38072447)
5. Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S et al. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology 1988; 94: 257-265. (Pubitemid 18054760)
6. Burke JP, Ferrante M, Dejaegher K, Watson RW, Docherty NG, De Hertogh G et al. Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflamm Bowel Dis 2008; 14: 1197-1204.
7. McKaig BC, Hughes K, Tighe PJ, Mahida YR. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002; 282: C172-C182. (Pubitemid 34662564)
8. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-827.
9. Mulsow JJ, Watson RW, Fitzpatrick JM, O'Connell PR. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg 2005; 242: 880-887. (Pubitemid 41714066)
10. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 1999; 13: 2105-2124.
11. Massagué J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000; 19: 1745-1754. (Pubitemid 30204386)
12. Beddy D, Mulsow J, Watson RW, Fitzpatrick JM, O'Connell PR. Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn's disease. Br J Surg 2006; 93: 1290-1296. (Pubitemid 44547031)
13. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080. (Pubitemid 38541684)
14. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl JMed 2005; 352: 1425-1435. (Pubitemid 40471450)
15. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6: 358-370. (Pubitemid 44314180)
16. Spitzer AL, Harris HW. Statins attenuate sepsis. Surgery 2006; 139: 283-287.
17. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001; 133: 1172-1180. (Pubitemid 32762429)
18. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104: 317-324. (Pubitemid 32666954)
19. Watts KL, Sampson EM, Schultz GS, Spiteri MA. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol 2005; 32: 290-300. (Pubitemid 40478304)
20. Louneva N, Huaman G, Fertala J, Jiménez SA. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum 2006; 54: 1298-1308. (Pubitemid 43672943)
21. Watts KL, Spiteri MA. Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1323-L1332. (Pubitemid 39507212)
22. Yang JY, Widmann C. The RasGAP N-terminal fragment generated by caspase cleavage protects cells in a Ras/PI3K/Akt-dependent manner that does not rely on NFkappa B activation. J Biol Chem 2002; 277: 14641-14646.
23. Pucilowska JB, McNaughton KK, Mohapatra NK, Hoyt EC, Zimmermann EM, Sartor RB et al. IGF-I and procollagen alpha1(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1307-G1322.
24. Beddy DJ, Watson WR, Fitzpatrick JM, O'Connell PR. Critical involvement of stress-activated mitogen-activated protein kinases in the regulation of intracellular adhesion molecule-1 in serosal fibroblasts isolated from patients with Crohn's disease. J Am Coll Surg 2004; 199: 234-242. (Pubitemid 38962735)
25. Regan MC, Flavin BM, Fitzpatrick JM, O'Connell PR. Stricture formation in Crohn's disease: the role of intestinal fibroblasts. Ann Surg 2000; 231: 46-50. (Pubitemid 30043938)
26. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990-994. (Pubitemid 27485693)
27. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65: 241-269. (Pubitemid 26250610)
28. Niculescu-Duvaz I, Phanish MK, Colville-Nash P, Dockrell ME. The TGFbeta1-induced fibronectin in human renal proximal tubular epithelial cells is p38 MAP kinase dependent and Smad independent. Nephron Exp Nephrol 2007; 105: e108-e116. (Pubitemid 46496818)
29. Ott C, Iwanciw D, Graness A, Giehl K, Goppelt-Struebe M. Modulation of the expression of connective tissue growth factor by alterations of the cytoskeleton. J Biol Chem2003; 278: 44 305-44 311. (Pubitemid 37377176)
30. Muehlich S, Cicha I, Garlichs CD, Krueger B, Posern G, Goppelt-Struebe M. Actin-dependent regulation of connective tissue growth factor. Am J Physiol Cell Physiol 2007; 292: C1732-C1738. (Pubitemid 47080572)
31. Walia B, Wang L, Merlin D, Sitaraman SV. TGF-beta down-regulates IL-6 signaling in intestinal epithelial cells: critical role of SMAD-2. FASEB J 2003; 17: 2130-2132.
32. Inazaki K, Kanamaru Y, Kojima Y, Sueyoshi N, Okumura K, Kaneko K et al. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int 2004; 66: 597-604. (Pubitemid 38982001)
33. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004; 85: 47-64. (Pubitemid 38703594)
34. Roberts AB, Russo A, Felici A, Flanders KC. Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann N Y Acad Sci 2003; 995: 1-10. (Pubitemid 36706609)
35. Murphy M, Docherty NG, Griffin B, Howlin J, McArdle E, McMahon R et al. IHG-1 amplifies TGF-beta1 signaling and is increased in renal fibrosis. J Am Soc Nephrol 2008; 19: 1672-1680.
36. Kamaraju AK, Roberts AB. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J Biol Chem 2005; 280: 1024-1036.
37. Chen S, Crawford M, Day RM, Briones VR, Leader JE, Jose PA, et al. RhoA modulates Smad signaling during transforming growth factor-beta-induced smooth muscle differentiation. J Biol Chem 2006; 281: 1765-1770. (Pubitemid 43752494)
38. Edlund S, Landström M, Heldin CH, Aspenström P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 2002; 13: 902-914. (Pubitemid 34250354)
39. Vallance BA, Gunawan MI, Hewlett B, Bercik P, Van Kampen C, Galeazzi F et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol 2005; 289: G116-G128. (Pubitemid 40944230)